Machine learning-based lifetime breast cancer risk reclassification compared with the BOADICEA model: impact on screening recommendations
- PMID: 32565540
- PMCID: PMC7463251
- DOI: 10.1038/s41416-020-0937-0
Machine learning-based lifetime breast cancer risk reclassification compared with the BOADICEA model: impact on screening recommendations
Abstract
Background: The clinical utility of machine-learning (ML) algorithms for breast cancer risk prediction and screening practices is unknown. We compared classification of lifetime breast cancer risk based on ML and the BOADICEA model. We explored the differences in risk classification and their clinical impact on screening practices.
Methods: We used three different ML algorithms and the BOADICEA model to estimate lifetime breast cancer risk in a sample of 112,587 individuals from 2481 families from the Oncogenetic Unit, Geneva University Hospitals. Performance of algorithms was evaluated using the area under the receiver operating characteristic (AU-ROC) curve. Risk reclassification was compared for 36,146 breast cancer-free women of ages 20-80. The impact on recommendations for mammography surveillance was based on the Swiss Surveillance Protocol.
Results: The predictive accuracy of ML-based algorithms (0.843 ≤ AU-ROC ≤ 0.889) was superior to BOADICEA (AU-ROC = 0.639) and reclassified 35.3% of women in different risk categories. The largest reclassification (20.8%) was observed in women characterised as 'near population' risk by BOADICEA. Reclassification had the largest impact on screening practices of women younger than 50.
Conclusion: ML-based reclassification of lifetime breast cancer risk occurred in approximately one in three women. Reclassification is important for younger women because it impacts clinical decision- making for the initiation of screening.
Conflict of interest statement
The authors declare no competing interests.
Figures


Similar articles
-
Machine learning techniques for personalized breast cancer risk prediction: comparison with the BCRAT and BOADICEA models.Breast Cancer Res. 2019 Jun 20;21(1):75. doi: 10.1186/s13058-019-1158-4. Breast Cancer Res. 2019. PMID: 31221197 Free PMC article.
-
Validating the IBIS and BOADICEA Models for Predicting Breast Cancer Risk in the Iranian Population.Clin Breast Cancer. 2017 Jun;17(3):e113-e118. doi: 10.1016/j.clbc.2017.01.003. Epub 2017 Jan 18. Clin Breast Cancer. 2017. PMID: 28216418
-
10-year performance of four models of breast cancer risk: a validation study.Lancet Oncol. 2019 Apr;20(4):504-517. doi: 10.1016/S1470-2045(18)30902-1. Epub 2019 Feb 21. Lancet Oncol. 2019. PMID: 30799262
-
Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk.J Natl Cancer Inst. 2015 May 8;107(7):djv124. doi: 10.1093/jnci/djv124. Print 2015 Jul. J Natl Cancer Inst. 2015. PMID: 25956172 Free PMC article.
-
Machine learning models in breast cancer survival prediction.Technol Health Care. 2016;24(1):31-42. doi: 10.3233/THC-151071. Technol Health Care. 2016. PMID: 26409558
Cited by
-
Adoption of artificial intelligence in breast imaging: evaluation, ethical constraints and limitations.Br J Cancer. 2021 Jul;125(1):15-22. doi: 10.1038/s41416-021-01333-w. Epub 2021 Mar 26. Br J Cancer. 2021. PMID: 33772149 Free PMC article. Review.
-
An introduction to machine learning for clinicians: How can machine learning augment knowledge in geriatric oncology?J Geriatr Oncol. 2021 Nov;12(8):1159-1163. doi: 10.1016/j.jgo.2021.03.012. Epub 2021 Mar 29. J Geriatr Oncol. 2021. PMID: 33795205 Free PMC article. No abstract available.
-
Breast cancer screening and early diagnosis in Chinese women.Cancer Biol Med. 2022 Apr 5;19(4):450-67. doi: 10.20892/j.issn.2095-3941.2021.0676. Cancer Biol Med. 2022. PMID: 35380032 Free PMC article. Review.
-
Empowering cancer prevention with AI: unlocking new frontiers in prediction, diagnosis, and intervention.Cancer Causes Control. 2025 Apr;36(4):353-367. doi: 10.1007/s10552-024-01942-9. Epub 2024 Dec 13. Cancer Causes Control. 2025. PMID: 39672997 Review.
-
Global guidelines for breast cancer screening: A systematic review.Breast. 2022 Aug;64:85-99. doi: 10.1016/j.breast.2022.04.003. Epub 2022 Apr 19. Breast. 2022. PMID: 35636342 Free PMC article.
References
-
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. cancer. 2015;136:E359–E386. - PubMed
-
- Bouchardy Magnin, C., Pury, P., Lorez, M., Clough-Gorr, K. & Bordoni, A. Trends in breast cancer survival in Switzerland. Bull. suisse du Cancer4, 326–328 (2011).
-
- Jones T, Duquette D, Underhill M, Ming C, Mendelsohn-Victor KE, Anderson B, et al. Surveillance for cancer recurrence in long-term young breast cancer survivors randomly selected from a statewide cancer registry. Breast Cancer Res Treat. 2018;169:141–152. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical